10x Genomics (TXG) Operating Margin (2018 - 2026)

10x Genomics has disclosed Operating Margin across 9 years of filings, most recently posting 11.3% for Q1 2026.

• Operating Margin for Q1 2026 came in at 11.3%, up 1409.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 6.06% (up 2154.0% YoY), and the FY2025 annual result was 9.49%, up 2237.0% from the prior year.
• Operating Margin came in at 11.3% for Q1 2026 at 10x Genomics, up from 11.77% in the prior quarter.
• In the past five years, Operating Margin ranged from a high of 17.42% in Q2 2025 to a low of 61.7% in Q3 2023.
• The 5-year median for Operating Margin is 30.0% (2023), against an average of 28.91%.
• Across the five-year window, Operating Margin plunged 4616 bps in 2022 and soared 4468 bps in 2025, its largest moves.
• 10x Genomics' Operating Margin stood at 14.78% in 2022, then slumped by 103 bps to 30.0% in 2023, then slipped by 1 bps to 30.2% in 2024, then soared by 61 bps to 11.77% in 2025, then climbed by 4 bps to 11.3% in 2026.
• The last three Operating Margin figures came in at 11.3% (Q1 2026), 11.77% (Q4 2025), and 21.64% (Q3 2025), per Business Quant data.